Screener / SEC EDGAR /CIK 0001368514 /10-K filed Feb 25, 2026, compared with Mar 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Adma Biologics, Inc. ADMA

Compare with peers Embed
New in the 10-K 10 paragraphs with nothing like them in the 10-K filed Mar 18, 2025 New in the 10-Q 9 paragraphs not in the 10-Q filed Aug 5, 2026 10-Q against the 10-K 39 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 18, 2025. A box jumps to the paragraph as filed, below.

10 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

10 paragraphs in Risk Factors of the 10-K filed Feb 25, 2026 with nothing like them in the 10-K filed Mar 18, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

Issues in the development and use of AI may result in reputational harm and increased liability exposure.

Read in the 10-K

Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease.

Read in the 10-K

Regulatory authorities may not accept data from foreign clinical studies or sites or may find that such data is not sufficiently representative of the population of the approving jurisdiction;

Read in the 10-K

our customers’ inability to comply with the terms of our distribution agreements; and

Read in the 10-K

On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM Credit Facilities”) consisting of (i) a term loan in the aggregate principal amount of $75 million, which was drawn in full on the JPM Closing Date, and (ii) a revolving credit facility in the aggregate principal amount of up to $225 million (collectively, the “JPM Loans”), none of which was drawn on the JPM Closing Date. The JPM Credit Facility has a maturity date of August 5, 2028.

Read in the 10-K
Show the other 3

There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent.

Read in the 10-K

Issues in the development and use of AI may result in reputational harm and increased liability exposure.

We have engaged a third-party firm to assist the Company with the development and deployment of an AI tool, ADMAlytics, to improve efficiencies across our supply chain, production, and commercial operations. This tool has been used to assist with activities including plasma pool composition and identifying other manufacturing efficiencies to streamline certain operational processes. While we have successfully implemented ADMAlytics in certain aspects of our commercial manufacturing and expanded its use throughout fiscal year 2025, the development, implementation, and ongoing use of AI technologies involve inherent risks. While ADMA has not experienced any issues to date, these risks include potential data inaccuracies, flawed assumptions, system errors, cybersecurity vulnerabilities, unintended outcomes, and difficulties in integrating AI-driven insights into complex and highly regulated manufacturing and operational environments. If ADMAlytics fails to perform as intended or produces unreliable or biased outputs, our reputation could be harmed and we could be subject to legal exposure, which could adversely affect our business, results of operations, and financial condition.

Read in the 10-K

There may be and have been changes in legal and regulatory requirements that may materially impact our results of operation.

We may face new risks as a result of changes in legal and regulatory requirements that may impact our operations and future prospects. For example, the 2025 change in the U.S. federal administration, as well as changes in legal standards, including the reduced level of judicial deference due to administrative agencies following a 2024 Supreme Court decision, may and does introduce regulatory and legal uncertainties that impact our operations. New federal or state laws and regulations may be, and have been, passed or enforced differently than they were before, requiring that we adapt, which we may not be able to do, and expend additional resources to ensure that we are able to comply. New laws and regulations, or the enforcement of the same, may also adversely restrict how we conduct our business. There could also be changes in the FDA’s approval standards that could impact our ability to obtain and maintain product approvals and market our product candidates or that otherwise could impact the competitive market for our products. Legal and regulatory changes may additionally impact how we may market and sell our products and how they are reimbursed. We cannot predict the exact nature of any changes that may take place or whether and how they may impact our business and results of operation.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before

New in the latest 10-Q

9 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Aug 5, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

10-Q

● our beliefs, plans and expectations regarding pending or threatened litigation and other legal proceedings;

Read in the 10-Q

Financial statements and notes

Nine Months Ended September 30, 2026 2025 (In thousands) ─────────────────────────────────────────────────────────────────────────────────────────────────────────── CASH FLOWS FROM OPERATING ACTIVITIES: Net income $133,034 $97,551 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 5,409 6,050 Gain on sale of plasma (7,980) - centers Loss on disposal of fixed 42 - assets Deferred income tax provision 2,569 9,848 Stock-based compensation 18,667 14,634 Amortization of debt discount 589 520 Loss - 3,336 on extinguishment of debt Amortization of license (107) (107) revenue Changes in operating assets and liabilities: Accounts receivable, net (10,794) (87,674) Inventories (59,650) (26,432) Prepaid expenses and other (2,514) (978) current assets Deposits and other assets 192 (261) Accounts payable 12,958 4,533 Accrued expenses 13,675 (5,427) Other current and non-current (934) (836) liabilities Net cash provided by 105,156 14,757 operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and (6,801) (21,491) equipment Acquisition of intangible (119) (124) assets Proceeds on the sales of 5,000 - assets held for sale Net cash used in investing (1,920) (21,615) activities CASH FLOWS FROM FINANCING ACTIVITIES: Ares term loan payments - (32,500) Ares revolving facility - (72,500) payments Ares revolving facility - 30,000 proceeds JPM term loan payments (1,875) (469) JPM revolving facility 125,000 75,000 proceeds Prepayment penalties on - (1,031) repayment of debt Taxes paid on vested (9,769) (9,383) restricted stock units Debt issuance costs - (2,224) Net proceeds from the 633 2,554 exercise of stock options Payment of end of term fee - (1,313) Acquisition of treasury stock (180,300) (23,038) Net cash used in financing (66,311) (34,904) activities Net increase (decrease) in cash and cash equivalents 36,925 (41,762) Cash and cash equivalents - beginning of period 87,630 103,147 Cash and cash equivalents - end of period $124,555 $61,385

Read in the 10-Q

Three stockholder derivative actions alleging substantially the same facts as the Securities Class Action have been filed to date: (1) Zunya v. Elms, et al., Case No. 2:26-cv-10811-ES-AME (D.N.J.) (the “Zunya Action”), filed on August 24, 2026; (2) Parris v. Elms, et al., Case No. 2:26-cv-11014-ES-AME (D.N.J.) (the “Parris Action”), filed on August 26, 2026; and (3) ES Trust v. Grossman, et al., Case No. 2:26-cv-11361-ES-AME (D.N.J.) (the “ES Trust Action,” and, collectively with the Zunya Action and Parris Action, the “Derivative Actions”), filed on September 2, 2026. The Derivative Actions were filed in the United States District Court for the District of New Jersey. The plaintiffs in the Derivative Actions purport to assert claims on the Company’s behalf against certain of the Company’s current and former executives and members of the Board for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, corporate waste, unjust enrichment, and violations of the Exchange Act. The Derivative Actions seek unspecified monetary and punitive damages, disgorgement of profits from the named defendants, an award of costs and expenses, including reasonable attorneys’ fees, and corporate governance reforms. On September 21, 2026, the Court consolidated the Derivative Actions with the new caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. The Company intends to move for a stay of the Derivative Actions pending resolution of the Securities Class Action.

Read in the 10-Q

The Company also received three demands to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law seeking documents related to the facts alleged in the Securities Class Action (the “Section 220 Demands”). The Company has responded to each of the Section 220 Demands and continues to discuss those responses with the requesting stockholders. The stockholders who served the Section 220 Demands may file additional Derivative Actions.

Read in the 10-Q

MD&A

Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025

Read in the 10-Q
Show the other 4

Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025

Read in the 10-Q

(b) Adjusted basic EPS is measured using basic weighted-average shares outstanding.

Read in the 10-Q

Legal proceedings

Three stockholder derivative actions alleging substantially the same facts as the Securities Class Action have been filed to date: (1) Zunya v. Elms, et al., Case No. 2:26-cv-10811-ES-AME (D.N.J.) (the “Zunya Action”), filed on August 24, 2026; (2) Parris v. Elms, et al., Case No. 2:26-cv-11014-ES-AME (D.N.J.) (the “Parris Action”), filed on August 26, 2026; and (3) ES Trust v. Grossman, et al., Case No. 2:26-cv-11361-ES-AME (D.N.J.) (the “ES Trust Action,” and, collectively with the Zunya Action and Parris Action, the “Derivative Actions”), filed on September 2, 2026. The Derivative Actions were filed in the United States District Court for the District of New Jersey. The plaintiffs in the Derivative Actions purport to assert claims on the Company’s behalf against certain of the Company’s current and former executives and members of our Board for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, corporate waste, unjust enrichment, and violations of the Securities Exchange Act of 1934, as amended. The Derivative Actions seek unspecified monetary and punitive damages, disgorgement of profits from the named defendants, an award of costs and expenses, including reasonable attorneys’ fees, and corporate governance reforms. On September 21, 2026, the Court consolidated the Derivative Actions with the new caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. We intend to move for a stay of the Derivative Actions pending resolution of the Securities Class Action.

Read in the 10-Q

We also received three demands to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law seeking documents related to the facts alleged in the Securities Class Action (the “Section 220 Demands”). We responded to each of the Section 220 Demands and continue to discuss those responses with the requesting stockholders. The stockholders who served the Section 220 Demands may file additional Derivative Actions.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 25, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
● We and certain of our directors and officers have been named as defendants in a securities class action lawsuit and in derivative actions. This lawsuit and these actions, and any similar or related proceedings that may be filed in the future, could result in substantial costs, divert management’s attention and resources from our business, and may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
We and certain of our directors and officers have been named as defendants in a securities class action lawsuit and in derivative actions. This lawsuit and these actions, and any similar or related proceedings that may be filed in the future, could result in substantial costs, divert management’s attention and resources from our business, and may have a material adverse effect on our business, financial condition, results of operations and cash flows.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
On July 10, 2026, a putative securities class action lawsuit, Mazzarino v. ADMA Biologics, Inc. et al., Case No. 2:26-cv-06918 (D.N.J.), was filed against us and certain of our directors and officers. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder and seeks monetary damages in an unspecified amount. The litigation remains at a preliminary stage. Additionally, there were derivative actions filed on the same conduct as alleged in the Mazzarino action that the Court subsequently consolidated into one action, bearing the caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. We have also received three demands to date for the inspection of books and records pursuant to Section 220 of the Delaware General Corporation Law, based on the allegations and claims set forth in the Mazzarino class action. We believe that the claims asserted in the class and derivative lawsuits are without merit, and we intend to vigorously defend against the actions.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
We may also become subject to additional securities class action lawsuits, stockholder derivative actions, regulatory inquiries, investigations or other proceedings arising out of the same or similar allegations.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
The ultimate outcomes of the litigation matters are inherently uncertain, and there can be no assurance that we will prevail. Regardless of the merits or ultimate outcome of the proceedings, defending against litigation can be costly and time-consuming and may divert the attention and resources of management and other personnel from the operation of our business. Any such litigation or proceedings may result in substantial defense costs, damages, settlement amounts, fines, penalties, reputational harm, increased regulatory scrutiny or other adverse consequences.

Read it in the 10-Q at sec.gov

Show the other 18
Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
At this time, we cannot reasonably estimate the ultimate outcomes of the litigation matters or the amount of any potential loss associated with the matters. If we are required to incur significant defense costs, enter into a settlement, pay damages or otherwise incur liabilities relating to the litigation matters, or if our insurance coverage is unavailable or insufficient to cover such costs, our business, financial condition, results of operations and cash flows could be materially adversely affected.

Read it in the 10-Q at sec.gov

Added10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Our Board is authorized to issue “blank check” preferred stock, with designations, rights and preferences as they may determine. Accordingly, our Board may in the future, without stockholder approval, issue shares of preferred stock with dividend, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of our common stock. This type of preferred stock could also be issued to discourage, delay, or prevent a change in our control. The ability to issue “blank check” preferred stock is a traditional anti-takeover measure. This provision in our charter documents makes it difficult for a majority stockholder to gain control of our company. Provisions like this may be beneficial to our management and our Board in a hostile tender offer and may have an adverse impact on stockholders who may want to participate in such a tender offer.

Read it in the 10-Q at sec.gov

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally and are therefore subject to potential tariffs, which could be passed along to us in whole or in part and adversely impact our results of operations, and supply disruptions in the event of fire, weather related events such as hurricanes, earthquakes, wind and rain, international conflicts, strikes, embargoes, trade and sanction requirements and limits, other acts of God or force majeure events or global health occurrences and emergencies. emergencies which could materially impact our ability to manufacture our products and product candidates and therefore adversely impact our business and results of operations.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
On August 5, 2025 (the “JPM the JPM Closing Date”), Date, we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM the JPM Credit Agreement”) Agreement (see “Liquidity and Capital Resources”).

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility, our new real estate in Boca Raton, FL Florida acquired in July 2025 and our plasma collection facilities, are vulnerable to natural disasters (including as a result of climate change), such as interruption by fires, weather related events such as hurricanes, earthquakes, wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, breakdown including the disruption or misalignment of specialized laboratory machinery, cyberattacks on our operations and information technology systems as well as the systems of our customers, suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims and events beyond our control.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Under the ACA and the companion Healthcare and Education Reconciliation Act of 2010 (which together are referred to as the “Healthcare Reform Law, Law”), payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but not limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
As of December 31, 2025, September 30, 2026, BlackRock, Inc., The Vanguard Group, Inc., State Street Corporation Corporation, Invesco Ltd., Vanguard Capital Management LLC and our directors and executive officers and their affiliates collectively owned approximately 30% of the outstanding shares of our common stock.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the “Healthcare Reform Law”) Law introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
If we fail to obtain regulatory approval to market and sell our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished product candidates and the capital necessary to fund our operations will increase.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Any failure by us, our contract fill/finishers, or other third parties involved in the process for producing our products or product candidates to comply with the applicable manufacturing and regulatory requirements, including quality requirements, could place us and them at risk of regulatory enforcement actions, recalls and other adverse consequences, could adversely impact our products, products or product candidates, and could adversely impact patients receiving our products, products or product candidates, which may negatively impact our business and our ability to produce and supply products to meet commercial and clinical needs.

Read it in the 10-Q at sec.govThe 10-K sentence

Reworded10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
For example, in response to the ongoing conflict conflicts between Russia and Ukraine, and between the United States and Iran, the United States has imposed and may further impose, and other countries may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia.

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Although we are utilizing our FDA-approved fill/finish suite that we built at the Boca Facility for a portion of our finished drug product and although we receive raw material plasma from our ADMA BioCenters plasma collection facilities, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug product and to supply raw material source and high-titer RSV plasma.

Read it in the 10-Q at sec.govThe 10-K sentence

Quiet changes10-Q Nov 4, 2026 vs 10-K Feb 25, 2026
Following the any expansion of any of our manufacturing processes or the addition of new equipment, we will be required to validate the expanded facility, process changes if any and equipment, make the necessary submissions to FDA, obtain any FDA-required approvals and have it inspected by the FDA.

Read it in the 10-Q at sec.govThe 10-K sentence

The first 23 of 39 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Feb 25, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 18, 2025

jpm credit ×14jpm loans ×4jpmorgan taking ×3jpm closing ×3reputational harm ×2increased liability ×2liability exposure ×2lenders party ×2party thereto ×2time consuming ×2south america ×2america northern ×2northern africa ×2product approvals ×2payer claims ×2inflation reduction ×2
Where each one is used
  • jpm credit: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
  • jpm loans: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
  • jpmorgan taking: Our senior secured credit facility with JPMorgan Chase Bank, N.A. and certain other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in JPMorgan taking possession and disposing of any collateral.
  • jpm closing: On August 5, 2025 (the “JPM Closing Date”), we entered into a credit agreement with JPMorgan and certain other lenders party thereto (the “JPM Credit Agreement”) (see “Liquidity and Capital Resources”). The JPM Credit Agreement provides for a total of $300 million in senior secured credit facilities (the “JPM...
  • reputational harm: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
  • increased liability: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
  • liability exposure: Issues in the development and use of AI may result in reputational harm and increased liability exposure.
  • lenders party: Our senior secured credit facility with JPMorgan Chase Bank, N.A. and certain other lenders party thereto (collectively “JPMorgan”) is subject to acceleration in specified circumstances, which may result in JPMorgan taking possession and disposing of any collateral.

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

1 paragraph of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations.
In the 10-K filed Mar 18, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.